SABS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	8 941.00
Średni wolumen	13 547.00
Kapitalizacja rynkowa	37.82M
EPS	$0 ( 2024-04-01 )
Następna data zysków	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Kropotova Alexandra	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	Sullivan Eddie Joe	Buy	190 000	Employee Stock Option (right to buy)
2024-02-21	Bausch Christoph Lawrence	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	King Michael	Buy	115 000	Employee Stock Option (right to buy)
2024-02-21	Reich Samuel J	Buy	434 000	Employee Stock Option (right to buy)

INSIDER POWER
70.13
Last 88 transactions
Buy: 19 783 333 \| Sell: 3 137 658

SAB Biotherapeutics, Inc. Korelacja

10 Najbardziej pozytywne korelacje
RIDE	0.93
HNRG	0.929
TBLT	0.929
BCAN	0.927
CFRX	0.926
VRSN	0.925
SHBI	0.924
LGVN	0.922
ASLE	0.92
RMRM	0.919

10 Najbardziej negatywne korelacje
BRIV	-0.94
MSDA	-0.938
ADAL	-0.937
APXI	-0.932
VLAT	-0.929
HORI	-0.929
SGII	-0.929
BRIVU	-0.928
HCNE	-0.927
FTAA	-0.926

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SAB Biotherapeutics, Inc. Finanse

Annual	2023
Przychody:	$2.24M
Zysk brutto:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2023
Przychody:	$2.24M
Zysk brutto:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2022
Przychody:	$23.90M
Zysk brutto:	$20.61M (86.23 %)
EPS:	$-4.31

FY	2021
Przychody:	$60.88M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.394

Financial Reports:

No articles found.

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Aktualne aktualizacje dla SAB Biotherapeutics, Inc. [SABS]

Upcoming Earnings Alert